Every 10-Q that CG Oncology, Inc. (CGON) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CGON and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CGON filings page.
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company developing cretostimogene grenadenorepvec for bladder cancer and reported continuing losses as it invests in late-stage trials. For the three and six months ended June 30, 2026, net losses were $79.1 million and $139.3 million, respectively, with no approved products yet generating sales.
Cretostimogene is being advanced across multiple Phase 2 and Phase 3 studies in non-muscle invasive bladder cancer, including BOND-003, where monotherapy data showed a 75.5% complete response rate and 12- and 24-month duration of response rates of 64.2% and 60.1%, supporting a planned Biologics License Application in the fourth quarter of 2026.
As of June 30, 2026, cash, cash equivalents and marketable securities totaled $1,028.3 million, with working capital of $1,002.4 million, which management believes will fund operations for at least 12 months. A Delaware jury verdict, upheld by a July 2026 order, eliminated a potential 5% royalty on future cretostimogene sales and left ANI Pharmaceuticals without damages.
CG Oncology, Inc. reported a larger net loss as it invests heavily in late-stage bladder cancer programs while strengthening its balance sheet. For the three months ended March 31, 2026, total revenue was $1.1 million, including $1.1 million of commercial and development revenue from Biovire and a small amount of license revenue. Operating expenses rose to $67.5 million, driven by $43.7 million in research and development and $20.8 million in general and administrative costs, leading to a net loss of $60.2 million versus $34.5 million a year earlier.
The company ended March 31, 2026 with $1,076.2 million in cash, cash equivalents and marketable securities, supported by $391.4 million of net proceeds from an at-the-market offering during the quarter. As of that date, accumulated deficit was $439.2 million and 88,007,761 common shares were outstanding. Management believes existing funds can support operations for at least twelve months while it advances its Biologics License Application for cretostimogene grenadenorepvec in non-muscle invasive bladder cancer.
CG Oncology, Inc. filed its Q3 2025 report, showing total revenues of $1.666 million and a net loss of $43.808 million for the quarter. Operating costs were driven by research and development $27.884 million and general and administrative $23.334 million, offset by interest income $7.321 million.
Liquidity remains strong with approximately $680.3 million of cash, cash equivalents and marketable securities and working capital ~$665.3 million as of September 30, 2025. Under its at‑the‑market program, the company sold 1,515,151 shares at $33.00 for net proceeds $48.7 million in Q3, and subsequently sold 2,343,967 shares for net proceeds $98.4 million after quarter‑end.
CG Oncology consolidated Biovire following a July 2025 conversion event, recognizing $12.805 million of goodwill and $1.700 million in intangible assets; the total consideration was $26.844 million. The company reported positive clinical updates for cretostimogene, including a 24‑month complete response rate of 41.8% (46/110) in BOND‑003 Cohort C and initiated its BLA submission in Q4 2025. In litigation, a jury verdict favored the company regarding ANI’s claims, with no damages and no 5% royalty owed.
CG Oncology, Inc. reported consolidated cash, cash equivalents and marketable securities of approximately $661.1 million and working capital of approximately $642.6 million, giving the company an explicit runway the company says extends into the first half of 2028. The company recorded a net loss of $75.9 million for the six months ended June 30, 2025, compared with a $35.8 million loss in the prior-year period, driven by higher research and development spending of $58.8 million and increased general and administrative costs of $32.2 million during the six months.
The balance sheet shows marketable securities of $646.4 million and a $26.0 million note receivable. Significant corporate developments disclosed include an Open Market Sale Agreement for up to $250.0 million (no sales as of June 30, 2025), a July 20, 2025 conversion and consolidation of an SPV, and a July 29, 2025 jury verdict unanimously rejecting ANI Pharmaceuticals' unjust enrichment claims so no royalty or damages are due under the disputed agreement.